Market research future published a cooked research report on global liquid biopsy market, the global liquid biopsy industry is expected to grow at a CAGR of ~ 28% during the period of 2015 to 2022.
Pune, India -- (SBWIRE) -- 02/01/2018 -- The Global Liquid Biopsy Market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%. The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc.
The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/710 .
Liquid Biopsy Market Highlights:
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Other market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Major Players of Global liquid biopsy market:
The major participants of this market are: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others.
Liquid Biopsy Market Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Liquid Biopsy Market Segmentation:
Global Liquid Biopsy Market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Order a Premium 90 Pages Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=710 .
Major Table of Content for Liquid Biopsy Market:
1 Report Prologue
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
Ask to expertise @ https://www.marketresearchfuture.com/sample_request/710 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.